ATI-052 — Topline data
H2 2026
Reaffirmed Expectation of Top Line Results in the Second Half of 2026 from Two Ongoing Phase 1b POC Trials of ATI- 052: ATI-052 is being assessed in POC trials in both atopic dermatitis (AD) and asthma.Source filing
ACRS biotech catalysts & pipeline
ACLARIS THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
next-generation JAK-Sparing ITK Inhibitor — IND submission
H2 2026
Announced Intent to File Initial Investigational New Drug (IND) Application for Next-Generation JAK-Sparing ITK Inhibitor in the Second Half of 2026: Aclaris' next-generation ITK-selective inhibitors have extended half-lives and show complete ITK occupancy at very low doses.Source filing
ATI-9494 — IND submission
Q4 2026
We expect to file an IND application for ATI-9494 in the fourth quarter of 2026.Source filing
bosakitug — Topline data
Q4 2026
On Track for Expected Fourth Quarter 2026 Readout of Top Line Results from Phase 2 Trial of Investigational Anti-TSLP Monoclonal Antibody Bosakitug: Enrollment is complete in this randomized, double-blind, placebo-controlled Phase 2 trial designed to evaluate bosakitug in 109 patients with AD.Source filing
undisclosed BsAb — IND submission
2027
Targeting first IND from bispecific antibody development efforts in 2027Source filing